number ahead expect growth
opportun continu encourag
number first quarter came ahead consensu vs
consensu product segment came model
due client closur strength servic segment gener number
ahead expect margin improv sinfoniarx saa softwar revenue
contribut prescribewel expect drive gm higher end
target year-end traction multipl product line encourag
near-term opportun health plan commun pharmacist market
intern provid market continu evolv focu value-bas
reimburs drive demand mtm solut expect
benefit reiter outperform target
vs estim consensu guid adj
ebitda vs estim consensu guid
adj ep vs estim consensu
guid mostli re-affirmed revenu guid re-affirmed
vs estim consensu estim adj
ebitda guid re-affirmed vs estim consensu
net loss revis vs
estim consensu expect
adj ebitda margin midpoint
dosem dealflow dosem ad nj fl system hospit
medwis yet fl dosem integr via help
dose parent med expect dosem footprint open door
compani medwis platform health system
meditur first cross-sel meditur launch first combin
integr staywel senior nc februari improv effici
satisfact plan roll rest share client
updat estim revenu adj ebitda estim
remain intact respect
increas gross margin expect expect reach higher end
goal year-end off-set increas invest keep
adj ebitda unchang interest expens decreas net incom level
year
year price histori
proprietari
reduc
technolog servic
medic safeti patient outcom
lower healthcar cost client
analyst certif import disclosur see disclosur
tabula rasa proprietari medic risk therapi solut
enabl signific shift care elderli
pace program all-inclus elderli
elimin advers drug event deal complex
multiple-med regimen home demograph tailwind
increas use multipl medic cost focu
drive penetr non-profit for-profit pace
program trhc solut mtm mrm
solut signific relev commerci health plan
see wave adopt sinfoniarx acquisit
acceler growth
continu growth sustain oper margin improv
contract new pace organ
new commerci contract emtm enhanc medic therapi
manag medwis solut
mix new live tilt commerci live penetr
new market entrant pose headlin risk potenti take
regulatori chang disrupt pace adopt
pt base sale price target still leav plenti upsid current level expect compani
lead way mrm mtm segment
regulatori turmoil disrupt pace could impact growth increas attent mtm could attract competit
revenu adj ebitda adj ep revenu rose vs
estim consensu guid adj ebitda vs estim
consensu guid adj ep vs estim consensu
gm adj ebitda gross margin came vs estim last
year gp estim adj ebitda margin vs
estim last year gp beat
guid introduc see revenu vs estim consensu
adj ebitda seen vs estim consensu net loss
expect vs estim consensu
guid mostli re-affirmed revenu guid re-affirmed vs
estim consensu estim adj ebitda guid re-affirmed vs
estim consensu net loss revis vs
estim consensu expect adj ebitda margin
midpoint guid
long-term gm rais given recent higher-margin softwar acquisit expect
high-end gm target also updat long-term target
new distributor/gpo improv product margin wont renew current distributor/
gpo contract result compani expect get product margin improv start
detail expect come
dosem dealflow dosem ad nj fl system hospit medwis yet
fl dosem integr via help dose parent med
asian letter intent repres hong kong taiwan visit trhc hq two week ago
medwis train sign letter intent certain asian countri doesnt see
meditur first cross-sel meditur launch first combin integr staywel
senior nc februari improv effici satisfact plan roll rest
share client
payer prospect list new cso kevin boesen focus nation payer commun
pharmaci region plan nation for-profit plan manag medicaid plan pace
similar special need plan
regulatori tailwind pcp model april announc new primari care pcp payment model
voluntari program aim medicar enrolle member one model pay provid
flat rate bonus upsid downsid keep patient home healthi fit
nice thrc offer believ
medic overload driver note senior med year
senior med lown report medic overload result us cultur
prescrib dtc ad pill everi ill write new script treat side effect drug
prescrib cascad excess focu clinic guidelin bp ade risk rise
addit med prevent
research develop
sale market
gener administr
depreci amort
total expens
incom tax
dilut prefer stock warrant
compani report oppenheim estim
